SCHEMBL1815990

SCHEMBL1815990

O=C(O)C1(Cc2cccc(Cl)c2)CCCN1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.46
SLC6A4 P31645 3/20 0.46
SLC6A3 Q01959 3/20 0.46
HRH3 Q9Y5N1 2/20 0.45
HSD11B1 P28845 1/20 0.44
SSTR1 P30872 1/20 0.42
SSTR4 P31391 1/20 0.42
HCAR2 Q8TDS4 1/20 0.41
CYP2D6 P10635 2/20 0.41
KCNH2 Q12809 1/20 0.41
CTBP2 P56545 1/20 0.40
EPHX2 P34913 1/20 0.39
ARG1 P05089 1/20 0.39
ARG2 P78540 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM3 P20309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29463986 1.00 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3HRH3HSD11B1
SCHEMBL23273783 1.00 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3HRH3HSD11B1
SCHEMBL1817633 0.85 HRH3 (0.59) SLC6A2SLC6A4SLC6A3HRH3HCAR2
SCHEMBL29274950 0.85 HRH3 (0.59) SLC6A2SLC6A4SLC6A3HRH3HCAR2
SCHEMBL29463983 0.85 HRH3 (0.59) SLC6A2SLC6A4SLC6A3HRH3HCAR2
SCHEMBL10956783 0.84 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3HRH3CYP2D6
SCHEMBL440476 0.84 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3HRH3CYP2D6
SCHEMBL414249 0.84 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3HRH3CYP2D6
SCHEMBL1816991 0.84 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3HRH3CYP2D6
SCHEMBL1817287 0.84 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3HRH3SSTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3154568-A1 NON-CANONICAL INSULINS AND THEIR USES California Institute of Technology (US) 2017-04-19 EP claimed
WO-2015191705-A1 NON-CANONICAL INSULINS AND THEIR USES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2015-12-17 WO claimed
US-20150353619-A1 Non-Canonical Insulins and Their Uses CALIFORNIA INSTITUTE OF TECHNOLOGY 2015-12-10 US claimed
US-20250249074-A1 GLUCOSE RESPONSIVE INSULINS PROTOMER TECHNOLOGIES INC. 2025-08-07 US disclosed
EP-4525919-A1 AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS Protomer Technologies Inc. (US) 2025-03-26 EP disclosed
US-12214018-B2 Glucose responsive insulins PROTOMER TECHNOLOGIES, INC. (US) 2025-02-04 US disclosed
US-20240425528-A1 AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS PROTOMER TECH INC (US) 2024-12-26 US disclosed
US-20240400637-A1 COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS PROTOMER TECHNOLOGIES INC. 2024-12-05 US disclosed
US-20240374735-A1 AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS PROTOMER TECHNOLOGIES INC. 2024-11-14 US disclosed
US-12139502-B2 Aromatic boron-containing compounds and related insulin analogs PROTOMER TECHNOLOGIES INC. (US) 2024-11-12 US disclosed
CN-113967258-B FAP-activated therapeutic agents and related uses 塔夫茨大学信托人 2024-07-02 CN disclosed
WO-2008128064-A2 TRUNCATED ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS TRUSTEES OF TUFTS COLLEGE (US) 2008-10-23 WO disclosed
WO-2008119005-A1 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV TRUSTEES OF TUFTS COLLEGE (US) 2008-10-02 WO disclosed
WO-2008118848-A1 N-SUBSTITUTED PEPTIDOMIMETIC INHIBITORS OF DIPEPTIDYLPEPTIDASE IV TRUSTEES OF TUFTS COLLEGE (US) 2008-10-02 WO disclosed
WO-2008116053-A2 FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-09-25 WO disclosed
WO-2008116054-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-09-25 WO disclosed
EP-1948243-A2 POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF Aeris Therapeutics, Inc. (US) 2008-07-30 EP disclosed
WO-2008022015-A2 RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-02-21 WO disclosed
WO-2007055950-A2 POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF AERIS THERAPEUTICS, INC. (US) 2007-05-18 WO disclosed
US-20070110813-A1 Polycation-polyanion complexes, compositions and methods of use thereof AERIS THERAPEUTICS, INC. (US) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250249074-A1 GLUCOSE RESPONSIVE INSULINS GLP1R, GPR119, IAPP SLC6A2 2940/4885SLC6A4 3233/4885SLC6A3 3023/4885
US-20240425528-A1 AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS IAPP, GPR119, INSR SLC6A2 554/4885SLC6A4 811/4885SLC6A3 297/4885
US-12214018-B2 Glucose responsive insulins GLP1R, GPR119, IAPP SLC6A2 2935/4885SLC6A4 3180/4885SLC6A3 3011/4885
US-20150353619-A1 Non-Canonical Insulins and Their Uses IAPP, IDE, INSR SLC6A2 2907/4885SLC6A4 2324/4885SLC6A3 3157/4885
US-20240400637-A1 COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS GPR119, INSR, IAPP SLC6A2 680/4885SLC6A4 1454/4885SLC6A3 80/4885
US-12139502-B2 Aromatic boron-containing compounds and related insulin analogs IAPP, GPR119, INSR SLC6A2 554/4885SLC6A4 811/4885SLC6A3 297/4885
US-20240374735-A1 AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS IAPP, GPR119, BRCA1 SLC6A2 216/4885SLC6A4 856/4885SLC6A3 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.